At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...

CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML). 1 ...

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

Discover why Syndax Pharmaceuticals (SNDX) is a strong buy, with FDA approvals, sales set to double by 2026, and major ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

Investors and analysts are invited to register to attend in person by emailing Nick Smith, Head of Investor Relations ( [email protected] ). A webcast will be available via the events page of the ...

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...

Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...

The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...

Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study It will be important to confirm this ...